Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Bon Secour St Francis Cancer Center
mi
from
Greenville, SC
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Bon Secour St Francis Cancer Center
mi
from
Greenville, SC
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
University of Texas Medical Center (El Paso)
mi
from
El Paso, TX
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
University of Texas Medical Center (El Paso)
mi
from
El Paso, TX
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Houston Methodist Hospital
mi
from
Houston, TX
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Houston Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
St. Luke's
mi
from
Houston, TX
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
St. Luke's
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Virginia Commonwealth University
mi
from
Richmond, VA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
Swedish Medical Center
mi
from
Seattle, WA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
The Blood Center of Wisconsin
mi
from
Milwaukee, WI
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
The Blood Center of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated:  6/26/2017
City of Hope
mi
from
Duarte, CA
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion
Status: Enrolling
Updated: 6/26/2017
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
TARGTEPO Treatment for Anemia in PD US Trial
Safety & Efficacy of Prolonged Physiologic EPO Level Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis Using MDGN201 TARGTEPO
Status: Enrolling
Updated:  7/12/2017
Clinical Advancement Center, PLLC
mi
from
San Antonio, TX
TARGTEPO Treatment for Anemia in PD US Trial
Safety & Efficacy of Prolonged Physiologic EPO Level Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis Using MDGN201 TARGTEPO
Status: Enrolling
Updated: 7/12/2017
Clinical Advancement Center, PLLC
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  7/17/2017
University of Illinois at Chicago Clinical Research Center
mi
from
Chicago, IL
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 7/17/2017
University of Illinois at Chicago Clinical Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  7/17/2017
University of Illinois Hospital & Health Sciences System
mi
from
Chicago, IL
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 7/17/2017
University of Illinois Hospital & Health Sciences System
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  7/17/2017
Boston Medical Center E7E
mi
from
Boston, MA
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 7/17/2017
Boston Medical Center E7E
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  7/17/2017
Boston University Medical Center
mi
from
Boston, MA
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 7/17/2017
Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  7/17/2017
Interfaith Medical Center
mi
from
Brooklyn, NY
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 7/17/2017
Interfaith Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  7/17/2017
Interfaith Medical Center
mi
from
Brooklyn, NY
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 7/17/2017
Interfaith Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  7/17/2017
UNC School of Medicine Clinical&Translational Research Ctr
mi
from
Chapel Hill, NC
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 7/17/2017
UNC School of Medicine Clinical&Translational Research Ctr
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  7/17/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 7/17/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  7/17/2017
UNC Hospitals' Investigational Drug Service Pharmacy
mi
from
Chapel Hill, NC
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 7/17/2017
UNC Hospitals' Investigational Drug Service Pharmacy
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  7/17/2017
Investigational Drug Services
mi
from
Richmond, VA
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 7/17/2017
Investigational Drug Services
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  7/17/2017
Boston Med Ctr
mi
from
Boston, MA
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 7/17/2017
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated:  7/17/2017
Pfizer Clinical Research Unit
mi
from
Brussels,
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease
Status: Enrolling
Updated: 7/17/2017
Pfizer Clinical Research Unit
mi
from
Brussels,
Click here to add this to my saved trials
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML
Status: Enrolling
Updated:  7/20/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML
Status: Enrolling
Updated: 7/20/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
Tulane University
mi
from
New Orleans, LA
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
Tulane University
mi
from
New Orleans, LA
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
Wayne State University
mi
from
Detroit, MI
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
University of Texas Southwestern
mi
from
Dallas, TX
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
All Children's Research Institute
mi
from
Saint Petersburg, FL
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
All Children's Research Institute
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated:  7/24/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Sickle Cell Disease Conditioning for Bone Marrow Transplant
Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study
Status: Enrolling
Updated: 7/24/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
Iron Deficiency in Female State Fair Attendees
Iron Deficiency, Depression, and Other Affective Disorders in Female State Fair Attendees
Status: Enrolling
Updated:  8/2/2017
University of Minnesota - Department of Food Science and Nutrition
mi
from
Saint Paul, MN
Iron Deficiency in Female State Fair Attendees
Iron Deficiency, Depression, and Other Affective Disorders in Female State Fair Attendees
Status: Enrolling
Updated: 8/2/2017
University of Minnesota - Department of Food Science and Nutrition
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer
Status: Enrolling
Updated:  8/8/2017
Gynecologic Oncology Group of Arizona
mi
from
Phoenix, AZ
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer
Status: Enrolling
Updated: 8/8/2017
Gynecologic Oncology Group of Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment
Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment
Status: Enrolling
Updated:  8/24/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment
Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment
Status: Enrolling
Updated: 8/24/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Status: Enrolling
Updated:  8/30/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Status: Enrolling
Updated: 8/30/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Status: Enrolling
Updated:  8/30/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia
Status: Enrolling
Updated: 8/30/2017
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
Status: Enrolling
Updated:  9/12/2017
University of Utah
mi
from
Salt Lake City, UT
Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
Status: Enrolling
Updated: 9/12/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease
A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Treatment of Vaso-Occlusive Crisis Associated With Sickle Cell Disease
Status: Enrolling
Updated:  9/15/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease
A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Treatment of Vaso-Occlusive Crisis Associated With Sickle Cell Disease
Status: Enrolling
Updated: 9/15/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia
Status: Enrolling
Updated:  9/15/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia
Status: Enrolling
Updated: 9/15/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia
Status: Enrolling
Updated:  9/15/2017
Tisch Cancer Center
mi
from
New York, NY
Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia
Status: Enrolling
Updated: 9/15/2017
Tisch Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Less Than Age 65 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm
Status: Enrolling
Updated:  9/18/2017
Stanford University
mi
from
Stanford, CA
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Less Than Age 65 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm
Status: Enrolling
Updated: 9/18/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Less Than Age 65 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm
Status: Enrolling
Updated:  9/18/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Less Than Age 65 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm
Status: Enrolling
Updated: 9/18/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Less Than Age 65 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm
Status: Enrolling
Updated:  9/18/2017
City of Hope Medical Center
mi
from
Duarte, CA
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Less Than Age 65 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm
Status: Enrolling
Updated: 9/18/2017
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Tempe, AZ
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Tempe, AZ
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
La Mesa, CA
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
La Mesa, CA
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Sacramento, CA
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Denver, CO
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Edgewater, FL
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Edgewater, FL
Click here to add this to my saved trials
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated:  9/20/2017
Clinical Research Facility
mi
from
Miami, FL
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis
Status: Enrolling
Updated: 9/20/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials